NovoCure Limited · NASDAQ:NVCR

NovoCure — Investor Presentation (October 2022)

35 slides from NovoCure's investor presentation, October 2022

  1. Slide 1: Novocure October 2022

    novecure’ Novocure October 2022 patientforward

  2. Slide 2: Forward-looking statements

    novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a

  3. Slide 3: Tumor Treating Fields are electric fields that kill cancer cells

    novocure’ Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer \ » N TeleEL_L DS cells via a variety of mechanisms “ANA TUMOR TREATING FIELDS THERAPY TTFields spare healthy cells because they have different properties than cancer cells across a range of tumo

  4. Slide 4: Tumor Treating Fields have multiple, distinct mechanisms of action

    novecure’ Tumor Treating Fields have multiple, distinct mechanisms of action interference of cell movement and disruption of 4 = , mitosis “ E mechanisms work together to selectively target and disrupt the progression of cancer cells, which can lead os downregulation of . to their death wT downstrea

  5. Slide 5: Optune intended as a treatment for adult patients with GBM

    Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

  6. Slide 6: Founded in 2000, now...

    FOUNDED IN 2000, NOW novecure’ PATIENTS TREATED TO DATE NET REVENUES IN Q3 2022 ONGOING PHASE 3/4 TRIALS WITH REGISTRATIONAL INTENT Together with our patients, we strive to extend survival in some of the PARTNERED IN CHINA patientforward® DIRECT DME OPERATIONS IN most aggressive forms of cancer U.S.

  7. Slide 7: GBM business of today drives investment in the future

    GBM business of today drives investment in the future net revenues! (USD in millions) operating expenses! (USD in millions) fit 5 2 @) $401.8 T | $400 ACTIVE PATIENTS ON THERAPY AS OF SEPT 30, 2022 $300 $300 ° /Th $200 $200 GROSS MARGIN ~ a‘ $970 CASH & SHORT-TERM $o ' so INVESTMENTS AS YTD 2018 YTD

  8. Slide 8: A comprehensive strategy for long-term growth

    novecure’ a comprehensive strategy for long-term growth , — , ~~ o ‘ a x / 4 = y / » t 5 3 \ ’ f \ \ ' PAB i , 7 “ARB 4 9. 0 Ry 4 —_) 80868 drive commercial advance deliver adoption clinical trials product innovation in approved in new indications to optimize indications and combinations TTFields th

  9. Slide 9: Drive commercial adoption

    novecure’ drive commercial adoption patientfo rward © 2022 Novocure GmbH 9

  10. Slide 10: Glioblastoma: malignant brain cancer

    novecure’ glioblastoma: malignant brain cancer WHO grade 4 15,000 cases diagnosed in the U.S. each yeart 49.1% of primary malignant brain tumors? 65: median age of newly diagnosed GBM patient2 14.6 to 16.7 months median overall survival® Early detection Is nearly 5-10% five-year survival rate imposs

  11. Slide 11: Optune: proven to extend patient survival

    novecure’ Optune: proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) na Hiticnonsin-2o9,andomssirinonts) —_%09__ 60 NEARLY HALF Log-rank P-value <0,001 ° f ea le vein —_ 087 HR (95% Cl) 0.63 (0.53-0.76) 43% 3 ee Re < o74 e

  12. Slide 12: Optune: greater exposure increased survival

    novecure’ Optune: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE 25 months P-0.05 22 months P<005 gw Optune + TMZ , = TMZ al 20 months 005 “on OF PATIENTS RECEIVED A SURVIVAL JM te montnsao0s BENEFIT FROM OPTUNE BECAUSE se months THEY USED IT >50% OF THE TIM

  13. Slide 13: Driving commercial growth in GBM

    driving commercial growth in GBM strengthen HCP increase patient COMMERCIAL PENETRATION recommendation demand IN NEWLY DIAGNOSED GBM IN ACTIVE MARKETS enter new geographic markets patient

  14. Slide 14: Advance clinical trials

    novecure’ advance clinical trials patientfo rward © 2022 Novocure GmbH 14

  15. Slide 15: Expand label in approved indications; investigate new indications

    expand label in approved indications holistic strategy to \ expand | T Fields clinical footprint investigate use in new indications © 2022 Novocure GmbH 15 patient

  16. Slide 16: Multiple late-stage, randomized pivotal trials set to read out in near-term

    novecure’ multiple late-stage, randomized pivotal trials set to read out in near-term | ENROLLMENT COMPLETE ENROLLMENT COMPLETE | ENGOT-ov50/ z AN war OP Innovaris METIS @ panovas Ovarian Cancer + Evaluating TTFields with * Evaluating TTFields with * Evaluating TTFields after + Evaluating TTFields w

  17. Slide 17: Late-stage pipeline offers substantial, near-term market expansion opportunity

    novecure’ late-stage pipeline offers substantial, near-term market expansion opportunity GLIOBLASTOMA LATE-STAGE PIPELINE 14x CURRENT MARKET OPPORUNITY PANOVA-3 Pancreatic Cancer ~35% penetrated in key markets METIS Brain Metastasis ENGOT-ov50/ INNOVATE-3 ‘Ovarian Cancer @ =1,000 addressable cases d

  18. Slide 18: Platform technology driving robust clinical pipeline

    novecure’ platform technology driving robust clinical pipeline ¢ ‘\ 1 ’ 4 \ 1 \ t v ? i 4 ---" Swany ‘ \ AY 1 H n a i’ mY ey my 4 \ iy 1 ii y pA 1 ‘ 1 4 1 ot i ae 1 Y bo patientforward PHASE 2 PHASE 3/4 APPROVED. a EF-07 primary newly diagnosed EF-14 brain glioblastoma TRIDENT cancer EF-41/KEYNOTE D

  19. Slide 19: Deliver product innovation

    novecure’ deliver product Innovation patientfo rward © 2022 Novocure GmbH 19

  20. Slide 20: Product roadmap to prioritize efficacy and ease of use

    oc product roadmap to prioritize efficacy and ease of use field generator arrays software applications next gen device flex arrays MAXPOINT™ in development limited market release upcoming planning software in development patient © 2022 Novocure GmbH 20

  21. Slide 21: Greater dose delivered can lead to increased efficacy

    greater dose delivered can lead to increased efficacy a TUMOR TREATING FIELDS DOSE DELIVERED TIME ON xX FIELD INTENSITY xX CONDUCTIVITY cm THERAPY TO TUMOR OF TISSUE — patient © 2022 Novocure GmbH 21 Ballo MT, et al. Correlationof Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnos

  22. Slide 22: Flex arrays increase coverage and dose

    flex arrays Increase Coverage and dose I _no_background 10 V/cm 10cm P CURRENT ARRAYS AP channel, 1,588 mAmps FLEX ARRAYS AP channel, 1,988 mAmps patient © 2022 Novocure GmbH 22 Data on file. Simulation of electric field distribution in healthy brain model

  23. Slide 23: Flex arrays designed for more efficient delivery

    novecure’ flex arrays designed for more efficient delivery ARRAY PERFORMANCE Average Current (2-Channels) 2,250 FLEX ARRAY 2,000 -e—_a—reSeease a uF 1750 CURRENT ARRAY of 1,500 1.250 SP SPP PP PP PPP PF PSP 8 LPP. P PPP PPP PPP PPP PPP PL SP LSB PPP PS Time Lapsed (Hours) ory PAP AV APS AVERAGE AVER

  24. Slide 24: Catalyst-rich through 2024

    novecure’ catalyst-rich through 2024 2021 2022 2023 2024 2024 ANTICIPATED PIVOTAL DATA LUNAR phase 3 INNOVATE-3 phase 3 LUNAR METIS IN 4 NEW INDICATIONS interim analysis interim analysis phase 3 data phase 3 data LUNAR phase 3 EF-31 gastric METIS phase 3 PANOVA-3 enrollment complete phase 2 data enr

  25. Slide 25: Together with our patients, we strive to extend survival

    together with our patients, 4 we Strive to extend survival in some of the most aggressive forms of cancer patientforward

  26. Slide 26: Appendix

    novocure’ appendix patientforward*

  27. Slide 27: Ongoing LUNAR trial in non-small cell lung cancer

    novecure’ ongoing LUNAR trial in non-small cell lung cancer LUNAR PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN? & ae mee CT q6wuntil dni [sels survival progression on screening 8 inhibitor/docetaxel progres follow-up visits (cliom-up or after platinum- fim baseline —— based therapy evaluatio

  28. Slide 28: Ongoing INNOVATE-3 trial in ovarian cancer

    novecure’ ongoing INNOVATE-S3 trial in ovarian cancer INNOVATE-3 PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! & TTFields + weekly [i CT/MRI scan q8w _ survival gernaore, s 7 paclitaxel until progressi follow-up a ae aS s weekly paclitaxel CT/MRI scan q8w [i survival S YP until progression f

  29. Slide 29: Ongoing METIS trial in brain metastases

    novecure’ ongoing METIS trial in brain metastases METIS PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! 6 Ee. Tumor Treating [i MRI q2m until ro 4 radiosurger Fields rogression screening and ji 8 a sey) pres baseline evaluation € 8 a _ MRI a2 til a] NY stereotactic a F An q2m unti g radiosurge

  30. Slide 30: Ongoing PANOVA-3 trial in pancreatic cancer

    novocure ongoing PANOVA-S trial in pancreatic C PANOVA-3 PHASE 3 PIV , OPEN-LABEL, RANDOMIZED TRIAL DESIGN* 5 el 7 CT g8w until post-PD survival screening and ic gemcitabine progression follow up visit follow-up q4w baseline fe evaluation 8 nab-paclitaxel + CT g8w until post-PD survival S gemcitabin

  31. Slide 31: Ongoing TRIDENT trial in newly diagnosed GBM

    novecure’ ongoing TRIDENT trial in newly diagnosed GBM TRIDENT PHASE 4 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! TTFields + RT TTFields + MRI q8w until + TMZ maintenance TMZ progression survival follow-up screening and baseline evaluation TTFields + MRI q8w until survival Ba spb, maintenance TMZ

  32. Slide 32: Ongoing KEYNOTE B36 trial in non-small cell lung cancer

    novecure’ ongoing KEYNOTE B36 trial in non-small cell lung cancer KEYNOTE B36 PHASE 2 PILOT TRIAL DESIGN* screening and TTFields (150 kHz) CT/MRI scan q9w until post-progression survival baseline evaluation JJ + pembrolizumab progression or 24 mo follow-up follow-up @ KEYNOTE B36 Lung Cancer STUDY D

  33. Slide 33: KEYNOTE D58 builds upon promising data from pilot 2-THE-TOP study

    novecure’ KEYNOTE D58 builds upon promising data from pilot 2-THE-TOP study N=26 patients Median PFS. N=26 patients Median OS oa 2-THE-TOP | 12.1 mos. 2 2-THE-TOP | 25.2 mos. = 9 EF-14 matched-control 7.9 mos. 2 Ll EF-14 matched-control 15.9 mos s = 2 (HR = 0.46; p=0.033) $ I (HR = 0.38; p=0.020) 8

  34. Slide 34: Optune Lua and Optune indications for use and important safety information

    novecure’ Optune Lua™ and Optune® indications for use and important safety information INDICATIONS Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of a

  35. Slide 35: Warnings and precautions

    novecure’ Optune Lua™ and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event

Novocure — Investor Presentation (October 2022) on 6ix